Formulation Facility I KANDLA UNIT I (GUJARAT, INDIA)
Installed Capacity
|
Dosage form |
Annual Capacity |
|---|---|
|
Tablets |
2062 Million |
|
General Capsules |
325 Million |
|
Sachet |
60 Million |
|
Injectable (Lyo- Vials) |
0.5 Million |
|
Injectable (Liquid Vials) |
1.8 Million |
|
Glass Ampoule |
18 Million |
|
Cream & Ointment |
4 Millions |
Approved by
BRAZIL
SOUTH AFRICA
TANZANIA
ZIMBABWE
UAE-MOH
KENYA
UGANDA
RUSSIA
KAZAKHSTAN
STATE-GMP WHO-CDSCO
Planned:
CANADA
EUROPE
MEXICO
UKRAINE
Formulation Facility II KANDLA UNIT II (GUJARAT, INDIA)
Installed Capacity
|
Dosage form |
Annual Capcity |
|---|---|
|
Transdermal Patch |
6 Million |
*Capacity as per shift basis
Approved by:
BRAZIL
AUSTRALIA
UAE-MOH
STATE-GMP WHO-CDSCO
Planned:
RUSSIA
EUROPE
Formulation Facility III DEHRADUN (UTTARAKHAND, INDIA)
Installed Capacity
|
Dosage form |
Annual Capacity |
|---|---|
|
Tablets |
3252 Million |
|
General Capsules |
144 Million |
|
Oral Liquid- Syrup |
1.14 Million |
|
Transdermal Patches |
0.98 Million |
|
Glass Vials |
1 Million |
|
Prefilled Syring |
6 Million |
*Capacity as per 3 shift basis
Approved by
CANADA
EUROPE
AUSTRALIA
BRAZIL
SOUTH AFRICA
UKRAINE
KENYA
UGANDA
SWITZERLAND
UAE_MOH
VIETNAM
STATE - GMP WHO-CDSCO
Planned:
RUSSIA
MALAYSIA
PHILIPPINES
API Facility IIPITHAMPUR (MADHYA PRADESH, INDIA)
ProductionCapacity (KL) - 60 Tons
Approved by
STATE-GMP WHO-CDSCO
Planned:
USFDA
EUROPE
WHO-CDSCO
API Facility I ANKLESHWAR (GUJARAT, INDIA)
Installed Capacity
|
Production |
Capacity (KL) |
|---|---|
|
Plant – I |
3.0KL |
|
Plant – II |
30.0KL |
|
Total |
33 KL (33Tons ) of annual production |
**Capacity as per 3 shift basis
Approved by:
-
USFDA
-
CANADA
-
EUROPE
-
JAPAN
-
BRAZIL
-
STATE-GMP WHO-CDSCO
Business Enquiries and Contact Information
Our Office
Rusan Pharma Ltd
58-D, Government Industrial Estate,
Charkop, Kandivali (West),
Mumbai - 400 067
Maharashtra. India
Copyright © Rusan Pharma. Designed by: WEBbrella Infotech